HRT Financial’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.1M Buy
795,168
+663,927
+506% +$10.2M 0.03% 541
2026
Q1
$1.82M Buy
131,241
+7,011
+6% +$112K ﹤0.01% 1676
2025
Q4
$2.02M Buy
+124,230
New +$2.03M 0.01% 1301
2025
Q1
– Sell
-98,357
Closed -$589K – 2455
2024
Q4
$589K Buy
98,357
+53,388
+119% +$294K ﹤0.01% 1359
2024
Q3
$230K Buy
+44,969
New +$196K ﹤0.01% 1913
2023
Q3
– Sell
-16,145
Closed -$108K – 2327
2023
Q2
$108K Sell
16,145
-89,783
-85% -$668K ﹤0.01% 1957
2023
Q1
$935K Sell
105,928
-21,422
-17% -$189K 0.01% 990
2022
Q4
$972K Sell
127,350
-64,518
-34% -$502K 0.01% 980
2022
Q3
$1.37M Sell
191,868
-20,615
-10% -$194K 0.01% 757
2022
Q2
$1.72M Buy
212,483
+4,755
+2% +$41.8K 0.02% 636
2022
Q1
$2.88M Buy
+207,728
New +$3.27M 0.02% 471
2021
Q2
– Sell
-67,955
Closed -$2.73M – 2772
2021
Q1
$2.73M Buy
+67,955
New +$3.68M 0.03% 468

Other funds holding ADPT

HRT Financial's ADPT Position: Q2 2026 in Review

HRT Financial increased its Adaptive Biotechnologies (ADPT) stake by 506% in Q2 2026, buying an estimated $10.2M and bringing the position to 795,168 shares worth $17.1M. The position accounts for 0.03% of the portfolio, ranked #541.

HRT Financial first reported a position in ADPT in Q1 2021 and has held it in 12 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • HRT Financial held 795,168 shares of Adaptive Biotechnologies worth $17.1M as of Q2 2026.
  • HRT Financial bought 663,927 Adaptive Biotechnologies shares in Q2 2026, an estimated $10.2M.
  • Adaptive Biotechnologies made up 0.03% of HRT Financial's portfolio in Q2 2026, its #541 holding.
  • HRT Financial first reported a position in Adaptive Biotechnologies in Q1 2021 and has held it in 12 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.